Pantoprazol Krka (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Krka, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Pantoprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces further erosion. - Peptic ulcer disease: supports ulcer healing and helps prevent recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens (as adjunct): enhances eradication success when combined with antibiotics.

Pantoprazol Krka may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: watery stools without blood. - Nausea: occasional feeling of queasiness. - Abdominal pain: cramp‑like discomfort. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhoea with abdominal pain. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: asymptomatic rise in ALT/AST. - Fracture risk with long‑term use: reduced bone mineral density. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Before starting Pantoprazol Krka, consider the following safety measures: - Assess renal function: adjust use in severe renal impairment. - Review liver status: use with caution in hepatic disease. - Evaluate for osteoporosis: long‑term therapy may affect bone health. - Monitor for infections: risk of gastrointestinal infections may increase. - Pregnancy and lactation: weigh benefits against potential risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazol Krka can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption. - Atazanavir: markedly decreased antiviral efficacy. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR. - Digoxin: possible increase in serum levels. - Methotrexate: reduced renal clearance at high doses. - Phenytoin: altered metabolism may change drug levels.